Previous 10 | Next 10 |
home / stock / tkphf / tkphf news
The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2019 Q1 earnings Read more ...
Takeda Pharmaceutical ( OTCPK:TKPHF ): Q1 Non-GAAP EPS of ¥128.00; GAAP EPS of -¥13.00. Revenue of ¥849.1B (+88.7% Y/Y) Press Release More news on: Takeda Pharmaceutical Company Limited, Takeda Pharmaceutical Company Limited, Earnings news and commentary, Hea...
By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...
By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...
Editor's note: Seeking Alpha is proud to welcome Chen Yang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Editor's note: Seekin...
Rhythm Pharmaceuticals ( RYTM ) is approaching a critical period. In Q3'19 the company is expected to report data from two phase 3 trials of its drug setmelanotide which are the major focus of this article. Setmelanotide in POMC deficiency obesity Setmelanotide is an agonist of the melanoc...
Takeda Pharmaceutical Co., Ltd. (TKPHF) Q4 2018 Results Earnings Conference Call May 14, 2019 4:00 AM ET Company Participants Andy Plump - Chief Medical & Scientific Officer and Director Christophe Weber - Chief Executive Officer Costa Saroukos - Chief Financial Officer J...
The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2018 Q4 earnings Read more ...
Takeda Pharmaceutical ( OTCPK:TKPHF ): FY Non-GAAP EPS of ¥459.30; GAAP EPS of ¥113.00. More news on: Takeda Pharmaceutical Company Limited, Takeda Pharmaceutical Company Limited, Earnings news and commentary, Healthcare stocks news, Read more ...
Minerva Neurosciences ( NERV ) is set to report data from multiple clinical trials in 2019 but roluperidone, which NERV is developing as a treatment for the negative symptoms of schizophrenia, is likely to get a disproportionate amount of attention. NERV and others developing in the negative...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Co Ltd Company Name:
TKPHF Stock Symbol:
OTCMKTS Market:
Takeda Pharmaceutical Co Ltd Website:
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...
JD.com Inc. (JD) is expected to report $0.56 for Q1 2024 Volkswagen AG (VLKAF) is expected to report for Q1 2024 CalAmp Corp. (CAMP) is expected to report for Q4 2024 Sonic Foundry Inc. (SOFO) is expected to report for Q2 2024 Moatable Inc ADR (R2RS:MU) is expected to report for Q...